MedTrace Logo

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

NCT05580172 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-10-17

No results posted yet for this study

Summary

Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer

Conditions

  • Safety Issues

Interventions

DRUG

RH324

polymolecular

Sponsors & Collaborators

  • ReHeva Biosciences,Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2024-06-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05580172 on ClinicalTrials.gov